Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference
February 26, 2025 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
February 18, 2025 10:21 ET
|
Cabaletta Bio
– Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining...
Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
February 18, 2025 07:00 ET
|
Cabaletta Bio
– Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining...
Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February
February 11, 2025 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference
January 29, 2025 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025
January 13, 2025 08:00 ET
|
Cabaletta Bio
– Company plans to meet with the FDA to align on registrational trial designs in 1H25 based on emerging clinical profile of resecabtagene autoleucel (rese-cel, formerly referred to as CABA-201) and...
Cabaletta Bio to Participate in Upcoming Investor Conferences in December
November 26, 2024 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
November 18, 2024 07:00 ET
|
Cabaletta Bio
– CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight patients and one previously reported ICANS event – –...
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
November 14, 2024 07:00 ET
|
Cabaletta Bio
– Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this weekend in oral and poster presentations at ACR...
Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
November 06, 2024 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...